Insider Selling: Xeris Biopharma (NASDAQ:XERS) Insider Sells $51,150.00 in Stock

Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) insider Steven Pieper sold 5,000 shares of the firm’s stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $10.23, for a total transaction of $51,150.00. Following the completion of the sale, the insider owned 1,346,053 shares of the company’s stock, valued at $13,770,122.19. The trade was a 0.37% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Steven Pieper also recently made the following trade(s):

• On Thursday, October 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $9.41, for a total transaction of $47,050.00.
• On Tuesday, September 1st, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00.
• On Wednesday, August 12th, Steven Pieper sold 5,000 shares of Xeris Biopharma stock. The shares were sold at an average price of $8.50, for a total transaction of $42,500.00.

Xeris Biopharma Stock Up 16.2%

NASDAQ:XERS opened at $15.20 on Friday. The firm has a 50-day simple moving average of $9.62 and a two-hundred day simple moving average of $7.62. The firm has a market cap of $2.77 billion, a P/E ratio of -303.94 and a beta of 0.61. Xeris Biopharma Holdings, Inc. has a fifty-two week low of $5.25 and a fifty-two week high of $15.21. The company has a debt-to-equity ratio of 17.00, a quick ratio of 1.02 and a current ratio of 1.45.

Xeris Biopharma (NASDAQ:XERS) last released its quarterly earnings results on Thursday, November 5th. The company reported $0.06 earnings per share for the quarter, beating analysts’ consensus estimates of $0.03 by $0.03. The business had revenue of $107.23 million during the quarter, compared to analyst estimates of $101.68 million. Xeris Biopharma had a positive return on equity of 338.21% and a negative net margin of 5.12%. Analysts predict that Xeris Biopharma Holdings, Inc. will post 0.07 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Xeris Biopharma

A number of large investors have recently added to or reduced their stakes in the company. BlackRock Inc. purchased a new position in shares of Xeris Biopharma during the second quarter valued at $115,042,000. Legal & General Group Plc acquired a new position in Xeris Biopharma during the second quarter valued at approximately $15,941,000. Parkman Healthcare Partners LLC purchased a new position in Xeris Biopharma during the 2nd quarter valued at about $14,316,000. Bank of America Corp DE bought a new stake in Xeris Biopharma during the second quarter valued at about $11,065,000. Finally, Vilga Financial Planning LLC acquired a new stake in shares of Xeris Biopharma in the 3rd quarter worth $10,134,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Key Xeris Biopharma News

Here are the key news stories impacting Xeris Biopharma this week:

• Positive Sentiment: Q3 results beat expectations: Xeris reported earnings of $0.06 per share versus a $0.03 consensus estimate, while revenue of $107.23 million exceeded forecasts of $101.68 million. The results provide evidence of stronger-than-expected performance. Xeris Biopharma Reports Third Quarter 2026 Financial Results and Business Highlights
• Positive Sentiment: Analysts raised targets: Oppenheimer reaffirmed its “outperform” rating and lifted its target to $21 from $18. HC Wainwright kept a “buy” rating and raised its target to $18 from $10. These revisions suggest greater optimism about Xeris’s prospects. Oppenheimer ratings HC Wainwright ratings
• Positive Sentiment: Recorlev sales outlook: CEO John Shannon reportedly sees the drug approaching $1 billion in annual sales three to four years earlier than previously expected, a potentially meaningful growth driver. CEO comments on Recorlev sales outlook
• Neutral Sentiment: Insider Kevin McCulloch sold 25,000 shares under a pre-arranged Rule 10b5-1 plan, a modest reduction; he retained more than 1.55 million shares. SEC Form 4 filing
• Negative Sentiment: Cautious analyst view: Piper Sandler reaffirmed “neutral” despite raising its target to $12 from $8. That target remains below the share price cited in the report, signaling valuation concerns. Piper Sandler ratings

Wall Street Analysts Forecast Growth

Several research analysts have recently issued reports on XERS shares. Barclays upped their price objective on Xeris Biopharma from $12.00 to $14.00 and gave the company an “overweight” rating in a research note on Tuesday, October 6th. Oppenheimer reiterated an “outperform” rating and issued a $21.00 price objective (up from $18.00) on shares of Xeris Biopharma in a research report on Friday. Weiss Ratings lowered shares of Xeris Biopharma from a “hold (c-)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Leerink Partners boosted their price objective on shares of Xeris Biopharma from $12.00 to $16.00 and gave the stock an “outperform” rating in a research note on Thursday, September 10th. Finally, Wall Street Zen raised shares of Xeris Biopharma from a “buy” rating to a “strong-buy” rating in a report on Saturday. Four equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $16.20.

Xeris Biopharma Company Profile

Xeris Biopharma, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for patients with endocrinology, gastroenterology and other serious or chronic conditions. The company uses proprietary formulation and delivery technologies designed to make complex therapies more stable, convenient and suitable for self-administration.

Xeris’ commercial portfolio includes Gvoke, a ready-to-use glucagon injection for the treatment of severe hypoglycemia in adults and children with diabetes; Recorlev (levoketoconazole), an oral therapy for endogenous hypercortisolemia associated with endogenous Cushing’s syndrome; and Keveyis (dichlorphenamide), a treatment for primary periodic paralysis.